Introduction {#section1-2036361319866539}
============

Small cell carcinoma of the uterine cervix (SCCC) is a rare and aggressive tumor, and the survival is poor regardless of the stage. SCCC accounts for 2% of all invasive cervical cancers, presents at a later FIGO stage at diagnosis (high frequency of lymph node and distant metastases), and has a median overall survival (OS) of only 22 months.^[@bibr1-2036361319866539]^ There is no established treatment for this carcinoma, due to its rarity. In general, clinicians have no other choice but to extrapolate the treatment options for cervical cancer (i.e. surgery followed by chemotherapy or combined chemoradiotherapy) according to the evidence obtained for small cell lung cancer (SCLC), particularly for chemotherapy.^[@bibr2-2036361319866539]^

Cervical cancer is one of the most common malignancies during pregnancy, with an incidence of 1.2 cases per 10,000 pregnancies.^[@bibr3-2036361319866539]^ Because of the paucity of large randomized trials examining pregnant patients with cervical cancer, the treatment is based on the data of non-pregnant women. In cases in which a pregnant woman with cervical cancer wants to continue the pregnancy, a delay in the initial therapy during the pregnancy presents a risk. For patients with stage IB or higher cervical cancer who opt for pregnancy preservation and are at the gestational age \<22--25 weeks at diagnosis, neoadjuvant chemotherapy is recommended to delay definitive therapy until after delivery.^[@bibr4-2036361319866539]^ However, it has been unclear whether this general principle can be applied to the rare and aggressive disease of SCCC.

We report the case of a woman with SCCC who underwent a radical hysterectomy with the fetus in situ during her pregnancy.

Case report {#section2-2036361319866539}
===========

A 33-year-old nulligravid Japanese woman at 15 weeks of gestation was referred to our institution with abnormal vaginal bleeding due to a uterine cervical tumor. She had become pregnant with the first trial of homologous artificial insemination. Surprisingly, her spectrum examination and screening Pap smear at 11 weeks of gestation did not detect any abnormality. She had no notable medical history and had not received a vaccination against HPV. The fetal growth was appropriate for the gestational date.

A speculum examination showed a bulky cervical tumor, without involvement of the vagina. Transvaginal echography showed a 5.4-cm-dia. tumor in the cervix, the uterus enlarged by the pregnancy, and a viable fetus. On pelvic and rectal examination, the tumor did not invade to the parametrium and rectal mucosa. Magnetic resonance imaging ([Figure 1(a)](#fig1-2036361319866539){ref-type="fig"}) and contrast-enhanced computed tomography showed that the tumor was confined to the cervix, and they indicated enlargement of intra-pelvic lymph nodes without evidence of nodal involvement, and no distant metastasis. A cervical biopsy was performed and the specimen was stained with hematoxylin--eosin (HE): the small-size cells of the tumor had a high nuclear-cytoplasmic ratio, finely granular nuclear choromatin, nuclear molding, and absent or inconspicuous nucleoli, suggesting SCCC ([Figure 2(a)--(c)](#fig2-2036361319866539){ref-type="fig"}). Immunostains revealed the absence of chromogranin A ([Figure 2(d)](#fig2-2036361319866539){ref-type="fig"}) but the presence of synaptophysin ([Figure 2(e)](#fig2-2036361319866539){ref-type="fig"}) and neural cell adhesion molecule ([Figure 2(f)](#fig2-2036361319866539){ref-type="fig"}), supporting the diagnosis of SCCC. Tumor markers including squamous cell carcinoma, carbohydrate antigen (CA) 125, CA19-9, CA72-4, carcinoembryonic antigen and neuron-specific enolase were within normal range. We diagnosed SCCC, FIGO stage IB2 (cT1b2N1M0).

![(a) Sagittal T2-weighted MRI revealed a cervical tumor growing mainly from the posterior uterine cervix (asterisk). (b) Front view of the nodular cervical tumor with a longitudinal incision of the anterior uterine wall (postoperative photo, white arrow).](10.1177_2036361319866539-fig1){#fig1-2036361319866539}

![(a) The tumor, with a high nuclear-cytoplasmic ratio, was growing in diffuse sheets, showing a rosette in some parts. Extensive necrosis was present. (b) The tumor consisted of dense sheets of small cells with scant cytoplasm, finely granular nuclear choromatin, frequent mitoses. Nucleoli are inconspicuous or absent. Nuclear molding was present. (c) HE stain at the same magnification ratio as the immunostains. (d) Immunostaining showed the absence of chromogranin A, but the presence of (e) synaptophysin and (f) neural cell adhesion molecule.](10.1177_2036361319866539-fig2){#fig2-2036361319866539}

We and another physician from whom the patient and her husband sought a second opinion offered surgery first, expecting histology-specific aggressive behavior and a lack of response to neoadjuvant chemotherapy. We performed a radical hysterectomy with the fetus in situ, a bilateral salpingo-oophorectomy, and pelvic and paraaortic lymphadenectomy at 18 weeks of gestation ([Figure 1(b)](#fig1-2036361319866539){ref-type="fig"}). At the laparotomy, there was no finding of lymphadenopathy or obturator lymph nodes. The pathologic examination of the resected specimen demonstrated no direct invasion of the vaginal wall, but lymph node metastasis in obturator and parametrial nodes (pT2bN1M0) was observed. Although we strongly recommended an adjuvant therapy, the patient and her husband selected routine post-operative surveillance only. Four months after the surgery, the patient had a systemic relapse of the disease, but she and her husband selected best supportive care only. She died 1 month after the relapse.

Discussion {#section3-2036361319866539}
==========

This case had two major clinical implications. First, early-stage SCCC should be treated with a radical hysterectomy and lymphadenectomy soon after diagnosis whether the patient is pregnant or not. Second, clinicians should consider the context of the aggressive behavior of SCCCs, and they should make saving the mother's life the top priority.

We performed a radical hysterectomy for SCCC at 18 weeks' gestation in this case. To our knowledge, this is the first report of a radical hysterectomy for SCCC during pregnancy. Since 1990, 10 cases of SCCC during pregnancy^[@bibr5-2036361319866539][@bibr6-2036361319866539]--[@bibr7-2036361319866539]^ were reported in the English literature ([Table 1](#table1-2036361319866539){ref-type="table"}). The initial treatment option depended on whether or not the fetus had extrauterine survival potential. Nine of the 10 patients diagnosed after 25 weeks' gestational age underwent elective cesarean section followed by a radical hysterectomy or chemotherapy. Teefey et al.^[@bibr7-2036361319866539]^ reported a case of SCCC during pregnancy diagnosed at 10 weeks' gestation, and they performed neoadjuvant chemotherapy with etoposide and cisplatin (EP/PE) because the patient declined a radical hysterectomy. In the present case, we initially performed a radical hysterectomy considering the gestational age at diagnosis and the estimated 10% 5-year survival rate which we calculated from the 10 above-mentioned cases. Although chemotherapy is reported to be relatively safe after the first trimester in breast cancer patients,^[@bibr8-2036361319866539]^ the efficacy and safety of performing neoadjuvant chemotherapy for the pregnant patients of FIGO stage IB2 or higher cervical cancer until the fetal maturation has not been established.^[@bibr9-2036361319866539]^ In addition, the Japan Society of Gynecologic Oncology (JSOG) guideline includes either surgery or radiotherapy for stage IIB cases.^[@bibr10-2036361319866539]^

###### 

Reported cases of small cell carcinoma of the uterine cervix during pregnancy since 1990.

![](10.1177_2036361319866539-table1)

  Author                                                 Year   Age   GA   FIGO stage   Treatment    Outcome
  ------------------------------------------------------ ------ ----- ---- ------------ ------------ ---------------
  Lewandowski and Copeland^[@bibr11-2036361319866539]^   1993   31    28   IB           CS, RH, CT   NED 51 months
  Chang et al.^[@bibr12-2036361319866539]^               1994   27    36   IB           CS, RH, CT   DOD 2 months
  Abeler et al.^[@bibr13-2036361319866539]^              1994   NA    NA   IB           CS, RH, CT   NED 54 months
  Perrin et al.^[@bibr14-2036361319866539]^              1996   23    25   IIA          CS, RH, CT   DOD 6 months
  Hirose et al.^[@bibr15-2036361319866539]^              1997   30    29   IIB          CS, RH, CT   DOD 7 months
  Balderston et al.^[@bibr16-2036361319866539]^          1998   22    30   IIA          CS, CT, RT   NED 66 months
  Leung et al.^[@bibr17-2036361319866539]^               1999   26    31   IB2          CS, CT, RT   NED 14 months
  Ohwada et al.^[@bibr6-2036361319866539]^               2001   27    27   IB1          CS, RT, CT   NED 13 months
  Teefey et al.^[@bibr7-2036361319866539]^               2012   31    10   IB1          CT, CS, RT   NED 24 months
  Liu et al.^[@bibr5-2036361319866539]^                  2014   25    32   IIA          CS, RT, CT   DOD 3 months
  Present case                                           2016   33    18   IB2          RT, BSC      DOD 5 months

Source: Modified from Ohwada et al.^[@bibr6-2036361319866539]^

GA: gestational age; CS: cesarean section; RH: radical hysterectomy; CT: chemotherapy; NED: no evidence of disease; DOD: dead of disease; NA: not available; RT: radiation therapy; BSC: best supportive care.

In the clinical document issued by the Society of Gynecologic Oncology, Gardner et al.^[@bibr18-2036361319866539]^ proposed that radical surgery is recommended for I--II SCCC, either primarily or after neoadjuvant chemotherapy. However, the benefit of adjuvant chemotherapy and its regimen remains controversial. Tian et al.^[@bibr19-2036361319866539]^ and Cohen et al.^[@bibr20-2036361319866539]^ independently reported that adjuvant chemotherapy for early-stage (less than IIA) SCCC after radical therapy did not improve the OS. Kuji et al.^[@bibr21-2036361319866539]^ reported that adjuvant chemotherapy significantly improved the progression-free survival (PFS) but not the OS in stage IB1--IIB SCCC cases. However, all of the findings mentioned above are based on retrospective analyses, not prospective studies. Although EP/PE therapy is the most frequent regimen for SCCC based on its use as a treatment for SCLC,^[@bibr22-2036361319866539]^ irinotecan and cisplatin (IP) for SCLC demonstrated significantly better PFS and OS compared to EP/PE in a randomized, Phase III study.^[@bibr2-2036361319866539]^ In the present case, we advised the patient to undergo adjuvant chemotherapy with IP or irradiation, but she declined adjuvant therapy because of uncertain benefit of adjuvant chemotherapy and poor prognosis of SCCC.

Conclusion {#section4-2036361319866539}
==========

We must consider the possibility of malignant disease of the uterine cervix when a pregnant woman complains of atypical vaginal bleeding. Although rare, SCCC can develop during pregnancy, and a radical hysterectomy can be a treatment option. The benefit of combined modality therapy including adjuvant chemotherapy for the OS of SCCC patients remains controversial. Further evaluation in more patients is necessary.
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